/

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

来源：Reuters发布于 2026-10-20

Drug developer Lycia Therapeutics targets $938 million valuation in US IPO

相关标的：LYCA

继续访问返回新闻

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。